skip to Main Content

Early Activity in Pancreatic Cancer With New Drug

Early Activity in Pancreatic Cancer With New Drug
Patients with locally advanced pancreatic cancer lived substantially longer compared with historical patients when treated with a drug that targets DNA repair in addition to chemoradiation, a small preliminary study showed.

Patients who received adavosertib (AZD1775) and chemoradiation had a median overall survival (OS) of 21.7 months. In contrast, prior evaluations of chemoradiation resulted in median OS of 12 to 14 months, reported Theodore S. Lawrence, MD, PhD, of Michigan Medicine in Ann Arbor, and colleagues. Read more . . .


Back To Top